Active DNA Aβ42 vaccination as immunotherapy for Alzheimer disease

Translational Neuroscience

Volumn 3, Issue 4, 2012, Pages 307-313

  Lambracht Washington, Doris ^a   Rosenberg, Roger N ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; Amyloid beta; Immunotherapy; Vaccination

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BAPINEUZUMAB; CAD 106; CRENEZUMAB; DNA VACCINE; FC RECEPTOR; FLORBETAPIR F 18; GAMMA INTERFERON; IMMUNOGLOBULIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 17; PLACEBO; PLASMID VECTOR; PRESENILIN 1; SOLANEZUMAB; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; ANTIBODY PRODUCTION; APP GENE; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); DISEASE MODEL; DNA IMMUNIZATION; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; GENE; GENE GUN; GENE MUTATION; GENETIC IMMUNIZATION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; MEDICAL DECISION MAKING; MENINGOENCEPHALITIS; MICROGLIA; NEUROFIBRILLARY TANGLE; NEUROPSYCHOLOGICAL TEST; NONHUMAN; PASSIVE IMMUNIZATION; PATHOGENESIS; PHAGOCYTOSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSEN1 GENE; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; T LYMPHOCYTE; TH1 CELL; TH2 CELL; TREATMENT OUTCOME;

EID: 84871417422     PISSN: 20813856     EISSN: 20816936     Source Type: Journal    
DOI: 10.2478/s13380-012-0037-6     Document Type: Review

References (47)

1. Götz J., Chen F., van Dorpe J., Nitsch R. M., Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Abeta 42 fibrils, Science, 2001, 293, 1491-1495 (Pubitemid 32807681)
2. Oddo S., Caccamo A., Kitazawa M., Tseng B. P., LaFerla F. M., Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease, Neurobiol. Aging, 2003, 24, 1063-1070 (Pubitemid 37487883)
3. Hardy J., New insights into the genetics of Alzheimer's disease, Ann. Med., 1996, 28, 255-258 (Pubitemid 26191063)
4. Selkoe D. J., Amyloid beta-protein and the genetics of Alzheimer's disease, J. Biol. Chem., 1996, 271, 18295-18298 (Pubitemid 26322675)
5. Hardy J., Selkoe D. J., The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics, Science, 2002, 297, 353-356 (Pubitemid 34790756)
6. Bertram L., Tanzi R. E., The current status of Alzheimer's disease genetics: what do we tell the patients?, Pharmacol. Res., 2004, 50, 385-396 (Pubitemid 39078530)
7. Rosenberg R. N., Translational research on the way to effective therapy for Alzheimer's disease, Arch. Gen. Psychiatry, 2005, 62, 1186- 1192 (Pubitemid 41586918)
8. Jonsson T., Atwal J. K., Steinberg S., Snaedal J., Jonsson P. V., Bjornsson S., et al., A mutation in APP protects against Alzheimer's disease and age-related cognitive decline, Nature, 2012, 488, 96-99
9. Wadman M., US government sets out Alzheimer's plan, Nature, 2012, 485, 426-427
10. Adolfsson O., Pihlgren M., Toni N., Varisco Y., Buccarello A. L., Antoniello K., et al., An Effector-reduced anti-β-amyloid (Aβ) antibody with unique Aβ binding properties promotes neuroprotection and glial engulfment of Aβ, J. Neurosci., 2012, 32, 9677-9689
11. Blennow K., Zetterberg H., Rinne J. O., Salloway S., Wei J., Black R., et al., Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease, Arch. Neurol., 2012, 69, 1002-1010
12. Farlow M., Arnold S. E., van Dyck C. H., Aisen P. S., Snider B. J., Porsteinsson A. P., et al., Safety and biomarker effects of solanezumab in patients with Alzheimer's disease, Alzheimers Dement., 2012, 8, 261-271
13. Relkin N. R., Szabo P., Adamiak B., Burgut T., Monthe C., Lent R. W., et al., 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease, Neurobiol. Aging, 2009, 30, 1728-1736
14. Relkin N., Bettger L., Tsakanikas D., Ravdin L., Three-year follow-up on the IVIg for Alzheimer's phase II study, Alzheimers Dement., 2012, 8, Suppl., P589/P3-381
15. Bateman R. J., Xiong C., Benzinger T. L., Fagan A. M., Goate A., Fox N. C., et al., Clinical and biomarker changes in dominantly inherited Alzheimer's disease, N. Engl. J. Med., 2012, 367, 795-804
16. Miller G., News focus: Stopping Alzheimer's before it starts, Science, 2012, 337, 790-792
17. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., et al., Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein, Nature, 1995, 373, 523-527
18. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., et al., Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse, Nature, 1999, 400, 173-177 (Pubitemid 29327547)
19. Janus C., Pearson J., McLaurin J., Mathews P. M., Jiang Y., Schmidt S. D., et al., A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease, Nature, 2000, 408, 979-982 (Pubitemid 32101644)
20. Morgan D., Diamond D. M., Gottschall P. E., Ugen K. E., Dickey C., Hardy J., et al., A beta peptide vaccination prevents memory loss inan animal model of Alzheimer's disease, Nature, 2000, 408, 982-985 (Pubitemid 32101645)
21. Fox N. C., Black R. S., Gilman S., Rossor M. N., Griffith S. G., Jenkins L., et al., Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease, Neurology, 2005, 64, 1563-1572 (Pubitemid 40617692)
22. Gilman S., Koller M., Black R. S., Jenkins L., Griffith S. G., Fox N. C., et al., Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial, Neurology, 2005, 64, 1553-1562 (Pubitemid 40617691)
23. Holmes C., Boche D., Wilkinson D., Yadegarfar G., Hopkins V., Bayer A., et al., Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial, Lancet, 2008, 372, 216-223 (Pubitemid 351978111)
24. Buttini M., Masliah E., Barbour R., Grajeda H., Motter R., Johnson- Wood K., et al., Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease, J. Neurosci., 2005, 5, 25, 9096-9101 (Pubitemid 41500817)
25. Serrano-Pozo A., William C. M., Ferrer I., Uro-Coste E., Delisle M. B., Maurage C. A., et al., Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology, Brain, 2010, 133, 1312-1327
26. Winblad B., Andreasen N., Minthon L., Floesser A., Imbert G., Dumortier T., et al., Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-inhuman study, Lancet Neurol., 2012, 11, 597-604
27. Bard F, Fox M, Friedrich S, Seubert P, Schenk D, Kinney GG, Yednock T. [Sustained levels of antibodies against Aβ in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic mice. Exp Neurol. 2012, ;238(1):38-43]
28. Monsonego A., Zota V., Karni A., Krieger J. I., Bar-Or A., Bitan G., et al., Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease, J. Clin. Invest., 2003, 112, 415-422 (Pubitemid 38063770)
29. Monsonego A., Imitola J., Petrovic S., Zota V., Nemirovsky A., Baron R., et al., Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease, Proc. Natl. Acad. Sci. USA, 2006, 103, 5048-5053
30. Qu B., Rosenberg R. N., Li L., Boyer P. J., Johnston S. A., Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease, Arch. Neurol., 2004, 61, 1859-1864 (Pubitemid 39612946)
31. Qu B., Boyer P. J., Johnston S. A., Hynan L. S., Rosenberg R. N., Aβ42 gene vaccination reduces brain amyloid plaque burden in transgenic mice, J. Neurol. Sci., 2006, 244, 151-158
32. Qu B.-X., Xiang Q., Li L., Johnston S. A., Hynan L. S., Rosenberg R. N., Aβ42 gene vaccine prevents Aβ42 deposition in brain of double transgenic mice, J. Neurol. Sci., 2007, 260, 204-213 (Pubitemid 47212229)
33. Qu B. X., Lambracht-Washington D., Fu M., Eagar T. N., Stüve O., Rosenberg R. N., Analysis of three plasmid systems for use in DNA A beta 42 immunization as therapy for Alzheimer's disease, Vaccine, 2010, 28, 5280-5287
34. Kim H. D., Jin J. J., Maxwell J. A., Fukuchi K., Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease, Immunol. Lett., 2007, 15, 30-38 (Pubitemid 47331686)
35. Movsesyan N., Ghochikyan A., Mkrtichyan M., Petrushina I., Davtyan H., Olkhanud P. B., et al., Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy, PLoS ONE, 2008, 3, e2124
36. DaSilva K. A., Brown M. E., McLaurin J., Reduced oligomeric and vascular amyloid-beta following immunization of TgCRND8 mice with an Alzheimer's DNA vaccine, Vaccine, 2009, 27, 1365-1376
37. Davtyan H., Mkrtichyan M., Movsesyan N., Petrushina I., Mamikonyan G., Cribbs D. H., et al., DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice, Gene Ther., 2010, 17, 261-271
38. Lambracht-Washington D., Qu B. X., Fu M., Eagar T. N., Stüve O., Rosenberg R. N., DNA beta-amyloid (1-42) trimer immunization for Alzheimer disease in a wild-type mouse model, JAMA, 2009, 302, 1796-1802
39. Lambracht-Washington D., Qu B. X., Fu M., Anderson L. D. Jr., Stüve O., Eagar T. N., et al., DNA Immunization against Amyloid beta 42 has high potential as safe therapy for Alzheimer's Disease as it diminishes antigen specific Th1 and Th17 cell proliferation, Cell. Mol. Neurobiol., 2011, 31, 867-874
40. Lemere C. A., Maier M., Peng Y., Jiang L., Seabrook T. J., Novel Abeta immunogens: is shorter better?, Curr. Alzheimer Res., 2007, 4, 427-436 (Pubitemid 47416637)
41. Maier M., Seabrook T. J., Lazo N. D., Jiang L., Das P., Janus C., et al., Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response, J. Neurosci., 2006, 26, 4717-4728 (Pubitemid 44315311)
42. Zou J., Yao Z., Zhang G., Wang H., Xu J., Yew D. T., et al., Vaccination of Alzheimer's model mice with adenovirus vector containing quadrivalent foldable Aβ1-15 reduces Aβ burden and behavioral impairment without Aβ-specific T cell response, J. Neurol. Sci., 2008,272, 87-98
43. Lambracht-Washington D., Qu B. X., Fu M., Stüve O., Eagar T. N., Rosenberg R. N., A regulatory immune response after DNA vaccination against amyloid beta 42, Alzheimers Dement., 2012, 8, Suppl., P201/P1-272
44. Subramanian S., Divya Shree A. N., Enhanced Th2 immunity after DNA prime-protein boost immunization with amyloid beta (1-42) plus CpG oligodeoxynucleotides in aged rats, Neurosci. Lett., 2008, 436, 219-222
45. Woodland D. L., Jump-starting the immune system: prime-boosting comes of age, Trends Immunol., 2004, 25, 98-104 (Pubitemid 38167491)
46. Lambracht-Washington D., Qu B. X., Fu M., Anderson L. D. Jr., Stüve O., Eagar T. N., et al., A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aβ42 DNA vaccine for Alzheimer disease, J. Neuroimmunol., 2012, (in press)
47. Fleisher A. S., Chen K., Liu X., Roontiva A., Thiyyagura P., Ayutyanont N., et al., Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease, Arch. Neurol., 2011, 68, 1404-1411